Scholarlink

Objective <p>To investigate oncological and reproductive outcomes in patients with mismatch repair-deficient (MMRd) endometrial endometrioid carcinoma (EEC) or atypical endometrial hyperplasia (AEH) undergoing fertility-preserving treatment to inform clinical management of this molecular subtype.</p> Methods <p>Clinical and pathological data from 14 patients with MMRd EEC or AEH who received fertility-preserving treatment at Peking Union Medical College Hospital from January 2020 to December 2023 were retrospectively analyzed.</p> Results <p>The mean age at diagnosis of the patients was 33.6 ± 4.2 years. Loss of MLH1/PMS2 expression was the most common immunohistochemical abnormality, followed by loss of MSH6, MSH2/MSH6, and PMS2 expression. Among the 12 patients who underwent germline genetic testing, pathogenic/likely pathogenic germline variants in MMR genes were identified in three patients. During the follow-up period (median 34.5 months, range 26–117 months), seven patients achieved complete remission (CR), with a median time to CR of 8 months. The recurrence rate among these patients was 57.1%, and the median time to recurrence was 11 months. Nine patients underwent surgery after treatment failure or recurrence, with postoperative pathology revealing histologic upgrading and/or metastasis in eight patients. Two patients successfully conceived through assisted reproductive technology and achieved live births.</p> Conclusion <p>Patients with MMRd EEC or AEH undergoing fertility-preserving treatment demonstrated relatively low remission rates, high recurrence rates, and suboptimal reproductive outcomes. Careful risk assessment and close surveillance for recurrence are warranted for patients desiring fertility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oncological and reproductive outcomes following fertility-preserving treatment in mismatch repair-deficient endometrial cancer or atypical endometrial hyperplasia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Tianyu Zhang,
  • Jie Yang,
  • Dongyan Cao,
  • Mei Yu,
  • Huanwen Wu,
  • Yang Xiang,
  • Xinyue Zhang,
  • Xuan Zong,
  • Rundong Zhang,
  • Xinyang Jin,
  • Kezhen Zhang,
  • Jing Zheng,
  • Jiaxin Yang

摘要

Objective

To investigate oncological and reproductive outcomes in patients with mismatch repair-deficient (MMRd) endometrial endometrioid carcinoma (EEC) or atypical endometrial hyperplasia (AEH) undergoing fertility-preserving treatment to inform clinical management of this molecular subtype.

Methods

Clinical and pathological data from 14 patients with MMRd EEC or AEH who received fertility-preserving treatment at Peking Union Medical College Hospital from January 2020 to December 2023 were retrospectively analyzed.

Results

The mean age at diagnosis of the patients was 33.6 ± 4.2 years. Loss of MLH1/PMS2 expression was the most common immunohistochemical abnormality, followed by loss of MSH6, MSH2/MSH6, and PMS2 expression. Among the 12 patients who underwent germline genetic testing, pathogenic/likely pathogenic germline variants in MMR genes were identified in three patients. During the follow-up period (median 34.5 months, range 26–117 months), seven patients achieved complete remission (CR), with a median time to CR of 8 months. The recurrence rate among these patients was 57.1%, and the median time to recurrence was 11 months. Nine patients underwent surgery after treatment failure or recurrence, with postoperative pathology revealing histologic upgrading and/or metastasis in eight patients. Two patients successfully conceived through assisted reproductive technology and achieved live births.

Conclusion

Patients with MMRd EEC or AEH undergoing fertility-preserving treatment demonstrated relatively low remission rates, high recurrence rates, and suboptimal reproductive outcomes. Careful risk assessment and close surveillance for recurrence are warranted for patients desiring fertility.